11th week of 2012 patent applcation highlights part 49 |
Patent application number | Title | Published |
20120065056 | CATALYST COMPOSITION PREPARATION AND USE - A bulk metal oxide catalyst composition of the general formula | 2012-03-15 |
20120065057 | PHOTOCATALYST BODY, PHOTOCATALYST DISPERSION, AND METHOD FOR MANUFACTURING PHOTOCATALYST BODY - According to one embodiment, a photocatalyst body satisfies at least one condition described below, (1) a ratio of an absorption intensity at a wave number of 3450 cm | 2012-03-15 |
20120065058 | EXHAUST GAS-PURIFYING CATALYST - An exhaust gas-purifying catalyst according to the present invention includes a substrate, a first catalytic layer facing the substrate and includes at least one precious metal selected from the group consisting of palladium and platinum, and alumina doped with an alkaline-earth metal element, and a second catalytic layer facing the substrate with the first catalytic layer interposed therebetween or intervening between the substrate and the first catalytic layer, the second catalytic layer includes rhodium and alumina doped with the alkaline-earth metal element. | 2012-03-15 |
20120065059 | LOW TEMPERATURE SULFUR TOLERANT TAR AND SULFUR REMOVAL WITH CONCOMITANT SYNTHESIS GAS CONDITIONING - A catalyst comprising of NiO; Al | 2012-03-15 |
20120065060 | SEED COATING COMPOSITION - The invention is directed to a seed coating composition, to a seed coating cocktail, to a method for preparing a coated seed, to a coated seed, and to the use of specific inorganic particles. The seed coating composition for a seed comprises water and at least 35 wt. % by weight of the coating composition of inorganic particles, wherein the mean particle size (D50) of said inorganic particles as measured by laser obscuration time technology is 250 μm or less. | 2012-03-15 |
20120065061 | ISOTHIAZOLYLOXYPHENYLAMIDINES AND THEIR USE AS FUNGICIDES - The present invention relates to isothiazolyloxyphenylamidines of the general formula (I), to a process for their preparation, to the use of the amidines according to the invention for controlling unwanted microorganisms, and also to a composition for this purpose which comprises the isothiazolyloxyphenylamidines according to the invention. Furthermore, the invention relates to a method for controlling unwanted microorganisms by applying the compounds according to the invention to the microorganisms and/or in their habitat. | 2012-03-15 |
20120065062 | Novel Heterocyclic Alkanol Derivatives - The present invention relates to novel heterocyclic alkanol derivatives, to processes for preparing these compounds, to compositions comprising these compounds and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection and in the protection of materials and as plant growth regulators. | 2012-03-15 |
20120065063 | 3-Aryl-4-(2,6-dimethylbenzylidene)isoxazol-5(4H)-ones as Fungicides - The invention relates to 3-aryl-4-(2,6-dimethylbenzylidene)isoxazol-5(4H)-ones, to agrochemically active salts thereof, to the use thereof and to methods and compositions for controlling phytopathogenic harmful fungi and insects in and/or on plants or in and/or on seed of plants, to processes for producing such compositions and treated seed, and to the use thereof for controlling phytopathogenic harmful fungi in agriculture, horticulture and forestry, in animal health, in the protection of materials and in the domestic and hygiene sector. The present invention further relates to a process for preparing isoxazolone derivatives. | 2012-03-15 |
20120065064 | NOVEL HERBICIDES - Compounds of the formula (I) wherein the substituents are as defined in claim | 2012-03-15 |
20120065065 | HERBICIDALLY ACTIVE PYRIDYLKETOSULTAMS - Herbicidally active pyridylketosultams of the general formula (I) and their use as herbicides are described. | 2012-03-15 |
20120065066 | NOVEL HERBICIDES - Compounds of formula (I), wherein the substituents are as defined in claim | 2012-03-15 |
20120065067 | PAMOIC ACID BLOCKS ETHYLENE SIGNALING - The disclosure provides methods and compositions for modulating ethylene and auxin signaling and ethylene production in plants. | 2012-03-15 |
20120065068 | AMINE AND AMINE OXIDE SURFACTANTS FOR CONTROLLING HERBICIDE SPRAY DRIFT - Spray drift during the application of an aqueous mixture of glyphosate and an auxinic herbicide is reduced by incorporating certain tertiary amine or tertiary amine oxide surfactants into the aqueous solution or mixture to be sprayed. | 2012-03-15 |
20120065069 | AGENT FOR REDUCING NICOTINE AND HARMFUL COMPONENTS IN TOBACCO LEAVES FOR USE IN FIELD CULTIVATION OF TOBACCO - One aspect of the invention provides an agent for reducing nicotine and harmful components in tobacco leaves for use in the field cultivation of tobacco. In one embodiment, the agent contains (in a weight percentage): salicylic acid 0.005-0.16%, naphthaleneacetic acid 0-0.003%, indoleacetic acid 0-0.015%, and clean water added to 100%. The composition can significantly reduce nicotine and harmful components in tobacco leaves by applying it to tobacco plant in top pruning period of tobacco. The combination of salicylic acid, naphthaleneacetic acid and indoleacetic acid provides synergic effect for reducing nicotine. The nicotine-reducing agent also can result in a yield increase and improve the aroma of tobacco. | 2012-03-15 |
20120065070 | METHOD FOR PRODUCING MICROCAPSULE - An object of the present invention is to provide a technique for producing a microcapsule containing a pesticidal compound in a fatty acid ester such as methyl O-acetylricinoleate, which delays the release timing of the pesticidal compound as compared to a conventional microcapsule. Provided is a method for producing a microcapsule, which comprises:
| 2012-03-15 |
20120065071 | METHODS TO PRODUCE POLYMER NANOPARTICLES AND FORMULATIONS OF ACTIVE INGREDIENTS - The present invention provides a composition including a polymer nanoparticle and at least one agricultural active compound incorporated with the nanoparticle, wherein the nanoparticle are less than 100 nm in diameter, and the polymer includes a polyelectrolyte. | 2012-03-15 |
20120065072 | SUPERCONDUCTING METALLIC GLASS TRANSITION-EDGE-SENSORS - A superconducting metallic glass transition-edge sensor (MGTES) and a method for fabricating the MGTES are provided. A single-layer superconducting amorphous metal alloy is deposited on a substrate. The single-layer superconducting amorphous metal alloy is an absorber for the MGTES and is electrically connected to a circuit configured for readout and biasing to sense electromagnetic radiation. | 2012-03-15 |
20120065073 | Magnetic Module - A magnetic field source is provided comprising a support structure upon which is positioned a conducting surface path of superconductor material. The support structure has an at least partially radially overlapping layer of material arranged in a spiral. A corresponding conducting surface path of superconductor material is arranged on the surface of the support structure such that the conducting path has a first point for the introduction of current and a second point for the extraction of current. | 2012-03-15 |
20120065074 | STRUCTURE TO REDUCE ELECTROPLATED STABILIZER CONTENT - A superconducting article includes first and second stacked conductor segments. The first stacked conductor segment includes first and second superconductive segments and has a nominal thickness t | 2012-03-15 |
20120065075 | METHOD OF DETERMINING A PREDISPOSITION TO ATRIAL FIBRILLATION (AF) IN A SUBJECT - The present invention concerns a method of determining a predisposition to atrial fibrillation (AF) in a subject comprising: determining the presence of at least one copy of a risk allele from at least one polymorphic marker in a sample from the subject, wherein the presence of at least one copy of the risk allele is indicative of a predisposition to AF, and wherein said at least one polymorphic marker is: a) rs4674485; b) rs1466560; c) rs1880039; d) rs3849387; e) rs7039; f) rs2952860; g) rs9312515; h) rs1897527; i) rs2299277; j) rs2418828; k) rs2385833; l) rs6717960; m) rs10510266; or n) a substitute polymorphic marker in linkage disequilibrium with any one of the polymorphic markers of a) to m). Also described are kits for determining a predisposition to atrial fibrillation (AF). | 2012-03-15 |
20120065076 | METHODS FOR THE DIAGNOSIS OF FETAL DISEASE - Methods are provided for detecting an aneuploidy in a fetus. These methods can be used to detect trisomy 13, 8 or 21, amongst other aneupoloidies. In some embodiments, the methods include selectively purifying fetal DNA from a maternal biological sample using the methylation status of a CpG containing genomic sequence and genotyping the fetus using the purified fetal DNA, thereby detecting aneuploidy in the fetus. | 2012-03-15 |
20120065077 | GENETIC FACTORS ASSOCIATED WITH INHIBITOR DEVELOPMENT IN HEMOPHILIA A - The present invention provides methods for predicting the risk of an individual developing antibodies to factor VIII by identifying a single nucleotide polymorphism of an immune response or immune modifier gene. The invention further provides oligonucleotides, diagnostic kits, microarrays, and isolated nucleic acids comprising single nucleotide polymorphisms of immune response or immune modifier genes. | 2012-03-15 |
20120065078 | METHOD FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES - The present invention refers to a method for the in vitro or in vivo diagnosis of cardiovascular diseases, in particular high blood pressure, stenosis, vessel occlusion and/or other thrombotic events, wherein the nucleotide at position 950 of a nucleic acid coding for the human ARK2 protein or the amino acid at position 298 of the human ARK2 protein of a sample of a person is determined as well as to the use of ARK2 for the development and/or production of a medicament for treating a cardiovascular disease. | 2012-03-15 |
20120065079 | METHOD FOR THE DETERMINATION OF P BLOOD GROUPS - The invention relates to a method to discriminate between the P | 2012-03-15 |
20120065080 | ACID CERAMIDASE POLYMORPHISMS AND METHODS OF PREDICTING TRAITS USING THE ACID CERAMIDASE POLYMORPHISMS - Provided are methods of predicting a trait in a subject including obtaining information about at least a portion of a polynucleotide sequence of the subject, the polynucleotide sequence encoding the acid ceramidase polypeptide, and using the information to predict the expression of the trait in the subject. Further provided are methods of developing a treatment plan for a subject with a disease or condition responsive to exercise. The methods may include obtaining information about at least a portion of a polynucleotide sequence of the subject, the polynucleotide sequence encoding the acid ceramidase polypeptide, using the information to predict a trait selected from maintaining an exercise program and physiological responsiveness to an exercise program, and developing a treatment plan for the subject to treat the disease or condition. | 2012-03-15 |
20120065081 | NUCLEIC ACID CONSTRUCTS AND METHODS OF USE - The present invention provides oligonucleotide constructs, sets of such oligonucleotide constructs, and methods of using such oligonucleotide constructs to provide validated sequences or sets of validated sequences corresponding to desired ROIs. Such validated ROIs and constructs containing these have a wide variety of uses, including in synthetic biology, quantitative nucleic acid analysis, polymorphism and/or mutation screening, and the like. | 2012-03-15 |
20120065082 | SINGLE-CELL MICROCHAMBER ARRAY - An apparatus for analyzing individual cell composition in a heterogeneous cell population may include, in one embodiment, a deposition plate having an array of microwells disposed therein, and a cover plate substantially overlying the deposition plate. A pair of electrodes may be associated with one or more of the microwells, and may be configured to generate an electric field within the associated microwell. | 2012-03-15 |
20120065083 | METHOD AND APPARATUS FOR PREDICTING SUSCEPTIBILITY TO A DEVELOPMENTAL DISORDER - The present invention provides a method of screening a subject for mutations in the TRAPPC9 gene that are associated with developmental disabilities. The present invention also provides proteins that are associated with developmental disabilities including a truncation of NIBP. Also provided are nucleotide sequences encoding such proteins and methods of screening subjects to identify nucleotide sequences or proteins associated with developmental disabilities. | 2012-03-15 |
20120065084 | METHODS AND TOOLS FOR PREDICTING THE EFFICIENCY OF ANTHRACYCLINES IN CANCER - A gene set, kit and method predict the efficiency of anthracyclines-based treatment of breast cancer. | 2012-03-15 |
20120065085 | Detection of chromosomal abnormalities associated with endometrial cancer - The methods and compositions described herein address the need for diagnostic method that could be offered to women during yearly checkups to allow for early detection, diagnosis and classification, and treatment of endometrial cancer. In addition, these methods and compositons addresse the current need for improving diagnostic accuracy of biopsy procedures in symptomatic patients. | 2012-03-15 |
20120065086 | Tape stripping methods for analysis of skin desease and pathological skin state - The present invention provides non-invasive methods for detecting, monitoring, and diagnosing skin disease and pathological skin states such as irritated skin and psoriasis. The methods include using tape stripping to analyze expression in epidermal samples, of one or more skin markers. In illustrative examples, the tape stripping is performed using pliable tape that has a rubber adhesive. Furthermore, the present invention provides methods for predicting and monitoring response to therapy for a skin disease, such as psoriasis or dermatitis. Finally, the methods can include the use of a microarray. | 2012-03-15 |
20120065087 | BIOMARKERS FOR DIAGNOSIS OF STROKE AND ITS CAUSES - The present invention provides compositions and methods for the diagnosis of the occurrence and cause of stroke. | 2012-03-15 |
20120065088 | SEQUENCE-SPECIFIC DETECTION OF NUCLEOTIDE SEQUENCES - A method for detecting the presence of a target nucleotide sequence in a sample of DNA is described herein in which a test sample comprising single stranded DNA is exposed to a DNA probe and a nicking endonuclease under conditions that would permit sequence-specific hybridization of the probe to a complementary target sequence. The probe comprises a sequence complementary to the target sequence to be detected and this sequence also includes a recognition sequence for the nicking endonuclease. If the sample contains the target sequence, the probe hybridizes to the target and is cleaved by the nicking endonuclease, which leaves the target intact. Observing the presence of probe cleaved by the nicking endonuclease indicates the presence of the target nucleotide sequence in the sample of DNA. | 2012-03-15 |
20120065089 | Method For Detecting And Distinguishing Intrahepatic Cholangiocarcinoma - Disclosed are a method for early, sensitively and reliably detecting and distinguishing intrahepatic cholangiocarcinoma in a malignant tumor occurring primarily in the liver in a simple way, and a kit therefor. In the method, a glycan biomarker consisting of a lectin WFA (Wisteria floribunda Agglutinin)-binding glycoprotein derived from intrahepatic cholangiocarcinoma is used as a cancer marker to detect intrahepatic cholangiocarcinoma by detecting the cancer marker in a test specimen. The method for detecting intrahepatic cholangiocarcinoma can clearly differentiate intrahepatic cholangiocarcinoma from hepatocellular carcinoma and enables early detection and determination with a performance clinically acceptable in terms of applicability, sensitivity and precision. | 2012-03-15 |
20120065090 | QUANTUM DOT-ENCODED BEAD SET FOR CALIBRATION AND QUANTIFICATION OF MULTIPLEXED ASSAYS, AND METHODS FOR THEIR USE - Control beads are disclosed that allow for improved quantitation of analytes in multiplexed bead assays. The control beads have a range of concentrations of calibration moieties that provide for the preparation of a titration curve. The titration curve can be used to quantify the concentration of the analytes. The titration curve can be used to correlate the signal obtained from a bead with the concentration (or absolute number of molecules) of the analyte bound to the bead. | 2012-03-15 |
20120065091 | DIRECT MULTIPLEX CHARACTERIZATION OF GENOMIC DNA - The invention is directed to novel methods of multiplexing nucleic acid reactions, including amplification, detection and genotyping. The invention relies on the use of precircle probes that are circularized in the presence of the corresponding target nucleic acids, cleaved, and then amplified. | 2012-03-15 |
20120065092 | FUSION ANALYTE CYTOMETRIC BEAD ASSAY, AND SYSTEMS AND KITS FOR PERFORMING THE SAME - Methods of detecting a fusion analyte in a sample are provided. Aspects of the methods include preparing a reaction mixture that includes a sample and a microparticle comprising a capture ligand for the fusion analyte, as well as first and second fluorescently labeled detector molecules. One of the first and second detector molecules specifically binds to the fusion analyte and the other specifically binds to a parent molecule thereof. Also provided are systems and kits configured for use in practicing methods of the invention. | 2012-03-15 |
20120065093 | Methods and Apparatus for Detecting Molecular Interactions Using FET Arrays - Methods and apparatuses relating to large scale FET arrays for analyte detection and measurement are provided. ChemFET (e.g., ISFET) arrays may be fabricated using conventional CMOS processing techniques based on improved FET pixel and array designs that increase measurement sensitivity and accuracy, and at the same time facilitate significantly small pixel sizes and dense arrays. Improved array control techniques provide for rapid data acquisition from large and dense arrays. Such arrays may be employed to detect a presence and/or concentration changes of various analyte types in a wide variety of chemical and/or biological processes. | 2012-03-15 |
20120065094 | METHODS AND KITS FOR DIAGNOSING OSTEOARTHRITIS AND PREDICTING PROGRESSION - This disclosure relates to methods and kits for diagnosing osteoarthritis and for determining the progression of osteoarthritis in a subject. | 2012-03-15 |
20120065095 | MARKERS OF RENAL TRANSPLANT REJECTION AND RENAL DAMAGE - The present invention relates to methods of detecting renal transplant rejection and other forms of renal damage. Protein markers or renal damage are provided, along with assays for detecting said markers. Also provided are methods for identifying markers of renal damage. | 2012-03-15 |
20120065096 | GENOTYPING TOOL FOR IMPROVING THE PROGNOSTIC AND CLINICAL MANAGEMENT OF MS PATIENTS - The invention relates to methods of evaluating MS severity based on analysis of single nucleotide polymorphisms (SNPs) and to products and kits for use in such methods. The methods include a method of assessing a multiple sclerosis disease severity phenotype in a human subject having multiple sclerosis, by determining the genotype of the subject at one or more positions of single nucleotide polymorphism (SNP) selected from: rs | 2012-03-15 |
20120065097 | METHOD OF DIAGNOSING POOR SURVIVAL PROGNOSIS COLON CANCER USING miR-106a - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-03-15 |
20120065098 | METHOD OF PREDICTING CHEMOTHERAPY EFFECTIVENESS IN COLON ADENOCARCINOMA PATIENTS, USING MIR-21 - The present invention provides novel methods and compositions for the diagnosis and treatment of colon cancers. In particular, the present invention provides diagnostics and prognostics for colon (including colon adenocarcinoma) cancer patients, wherein the methods related to measuring miR levels can predict poor survival. The invention also provides methods of identifying inhibitors of tumorigenesis. | 2012-03-15 |
20120065099 | AUTOMATED ANALYSIS OF MULTIPLEXED PROBE-TARGET INTERACTION PATTERNS: PATTERN MATCHING AND ALLELE IDENTIFICATION - Methods and algorithms for automated allele assignments within an integrated software environment are provided. These methods and algorithms offer a multiplicity of functionalities including: data management; system configuration including user authorization, training set analysis and probe masking; pattern analysis including string matching and probe flipping; and interactive redaction of data. The methods and algorithms further include methods of setting thresholds, refining thresholds, and probe masking of signals produced by probes which do not contribute significantly to discriminating among alleles. | 2012-03-15 |
20120065100 | PHOSPHODIESTERASE 9A AS PROSTATE CANCER MARKER - The present invention relates to phosphodiesterase 9A (PDE9A) for use as a marker for prostate cancer, and the use of PDE9A as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of prostate cancer, in particular hormone-resistant prostate cancer. | 2012-03-15 |
20120065101 | METHODS FOR REGULATING NEURAL DIFFERENTIATION - Methods of producing populations of predominantly astrocytes, neurons or oligodendrocytes are provided. In addition, methods of treating mammals having astroglial tumors, oligodendrocyte tumors, or neuronal tumors are provided. | 2012-03-15 |
20120065102 | METHOD FOR ANALYSIS OF NEURITE GROWTH - A method for the analysis of neurite growth is described, in which a substrate having an array pattern is provided, which has first regions on which neurons and cells similar to neurons can adhere, whereby the first regions are surrounded by second regions, in each instance, on which neurons and cells similar to neurons cannot adhere, whereby neurons or cells similar to neurons adhere only on the first regions of the array, and subsequently, the neurons or cells similar to neurons are exposed to one or multiple or no treatment(s), and during this/these treatment(s) and/or afterwards, the neurite outgrowths from the neurons or cells similar to neurons are analyzed by recognizing and quantifying the connections that are formed between the first regions by means of the neurite outgrowths. | 2012-03-15 |
20120065103 | Prolyl Endopeptidase Probes - Prolyl endopeptidase (PE) activity in lung samples is detected by contacting the lung sample with a probe comprising a —P—X— (or —X—P—, —P—X—P—) PE recognition site, wherein P is a prolyl bioisostere, X is a residue that is not a prolyl bioisostere or is a prolyl bioisostere flanked on each side by a residue that is not a prolyl bioisostere, and “-” is an amide bond, under conditions wherein PE activity of the sample specifically hydrolyzes an amide bond of the recognition site to generate an optical signal; and (b) detecting the signal. | 2012-03-15 |
20120065104 | COMPOSITIONS AND METHODS FOR A MEMBRANE PROTEIN CRYSTALLIZATION SCREENING KIT - The present invention comprises compositions and methods useful as a system for efficiently determining conditions that result in the formation of crystals of membrane proteins from solutions containing a membrane protein in a purified and soluble state. The system is comprised of two primary components, a solubility screen and a crystallization screen. Each component is a set of solutions. The present invention further provides a kit comprising solutions of the invention and an instructional material for the use thereof. | 2012-03-15 |
20120065105 | Chimeric Oligonucleotides for Ligation-Enhanced Nucleic Acid Detection, Methods and Compositions Therefor - Ligation-enhanced nucleic acid detection assay embodiments for detection of RNA or DNA are described. The assay embodiments rely on ligation of chimeric oligonucleotide probes to generate a template for amplification and detection. The assay embodiments are substantially independent of the fidelity of a polymerase for copying compromised nucleic acid. Very little background amplification is observed and as few as 1000 copies of target nucleic acid can be detected. Method embodiments are particularly adept for detection of RNA from compromised samples such as formalin-fixed and paraffin-embedded samples. Heavily degraded and cross-linked nucleic acids of compromised samples, in which classic quantitative real time PCR assays typically fail to adequately amplify signal, can be reliably detected and quantified. | 2012-03-15 |
20120065106 | Methods and Compositions for Enhanced Protein Expression and Purification - Methods for enhancing expression levels, secretion, and purification of heterologous fusion proteins in a host cell are disclosed. | 2012-03-15 |
20120065107 | REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY - Methods and reagents for classifying tumors and for identifying new tumor classes and subclasses. Methods for correlating tumor class or subclass with therapeutic regimen or outcome, for identifying appropriate (new or known) therapies for particular classes or subclasses, and for predicting outcomes based on class or subclass. New therapeutic agents and methods for the treatment of cancer. | 2012-03-15 |
20120065108 | FLUORINATED POLYMERIC MICROPARTICLES AND USES THEREOF AS FLUID REDUCING ADDITIVES - Fluorinated polymeric microparticles, processes for preparing them and uses thereof as additives for fluid loss control of drilling fluids and methods of fluid loss control of drilling fluid loss with fluorinated microparticles and uses of fluoropolymers as fluid loss control agents. Said fluorinated polymeric microparticles comprise one or more repeating units derived from one or more fluorinated monomers and one or more repeating units derived from one or more acrylate monomers. | 2012-03-15 |
20120065109 | Lubricating oil composition for transmission - Lubricating oil compositions for transmissions comprises (A) a lubricating base oil with a kinematic viscosity at 100° C. adjusted to 1.5 to 6 mm | 2012-03-15 |
20120065110 | Compounds and a Method of Lubricating an Internal Combustion Engine - The invention provides a lubricating composition containing an oil of lubricating viscosity and a product obtainable from a 1,4-conjugate addition of an aminocarboxylic acid to an activated olefin. The invention further relates to a method of lubricating an internal combustion engine by lubricating the engine with the lubricating composition. The invention further relates to the use of the product disclosed herein as a lead corrosion inhibitor. | 2012-03-15 |
20120065111 | BIODEGRADABLE LUBRICANT COMPOSITION - A biodegradable lubricating oil composition includes (A) an ester represented by a formula (1) below, the ester having a kinematic viscosity in a range from 300 mm | 2012-03-15 |
20120065112 | LUBRICANT COMPOSITION WITH IMPROVED VARNISH DEPOSIT RESISTANCE - In one embodiment, a lubricating oil with favorable deposit control is disclosed. The lubricating oil comprises, a major amount of base stock selected from the group consisting of Group II, Group III, GTL and any combination thereof, a mannich based dispersant comprising at least 0.1 and less than 2.0 weight percent of the lubricating oil, a demulsifier comprising apolyoxypropylene-polyoxyethylene block copolymer in tricresyl phosphate (TCP) demulsifier and apolyether glycol demulsifier, the demulsifiers comprising at least 0.002 to less than 2.0 weight percent of the lubricating oil, wherein the lubricating oil has a deposit control value less than 60 mg/kg using 504 hour 120° C. Dry TOST sludge test and an ASTM D-1401 emulsion characteristic of less than 60 minutes at 54° C. | 2012-03-15 |
20120065113 | FABRIC SOFTENER COMPOSITIONS AND METHODS OF MANUFACTURE THEREOF - Disclosed herein is a fabric softener composition comprising a fabric softener active compound that comprises a quarternary ammonium salt and/or an imidazolinium salt, and a ketal adduct of formula (12) | 2012-03-15 |
20120065114 | AMINE REACTION COMPOUNDS COMPRISING ONE OR MORE ACTIVE INGREDIENT - The present invention relates to a product of reaction between a primary and/or secondary amine and one or more active ingredients. By the present invention, there is provided a release of the active component over a longer period of time than by the use of the active itself. | 2012-03-15 |
20120065115 | CARA B Naturally - Shampoo / Body Wash - The hair shampoo/body wash composition of the present invention utilizes all natural plant derived components as a method for cleansing, conditioning and moisturizing the hair. The invention is a “tear-free” type composition and provides good moisturizing and gives a smooth, soft touch feel upon using on the skin and hair, and is excellent in stability. | 2012-03-15 |
20120065116 | CLEANING LIQUID AND CLEANING METHOD - Disclosed is a cleaning liquid which is capable of cleaning an object to be cleaned, to the surface of which cerium oxide adheres, by dissolving and removing cerium oxide in the form of cerium ions. A cleaning method using the cleaning liquid is also disclosed. The cleaning liquid for removing cerium oxide is characterized by containing hydrogen fluoride, at least one acid selected from the group consisting of hydrochloric acid, nitric acid, sulfuric acid, acetic acid, phosphoric acid, iodic acid and hydrobromic acid, and water. The cleaning liquid is also characterized by dissolving and removing cerium oxide in the form of cerium ions. | 2012-03-15 |
20120065117 | Article For Washing Coloured Textiles - The invention relates to an article for washing textiles able to absorb colorant substances ( | 2012-03-15 |
20120065118 | Modified silicone polymer as anti foam agent and detergent composition having the same - A modified silicone polymer as an anti foam agent, its preparation and detergent formulations involving selective organopolysiloxane antifoam composition/agent for use as fabric wash detergent adapted for excellent antifoaming effect in rinsing cycle with preferred defoaming effect in washing cycles. The anti foam agent for detergent formulations and the like is directed to not only save huge amount of waste water but also help to preserve massive amount precious clean water for desirable favorable use and application. It would provide for detergent formulations and the like which would favor both the washing and rinsing cycles and make washing of clothes/fabrics more convenient and user friendly apart from taking care of avoiding unnecessary wastage of valuable water and saving the environment from unnecessarily wastage of water in hand wash and/or semi automatic machine washing and the like. | 2012-03-15 |
20120065119 | Comb Polymers And The Use Thereof In Washing And Cleaning Agents - The invention relates to a comb polymer made of a polymer main chain and polyester side chains linked to said polymer main chain via ester groups, characterized in that (i) the polymer main chain is a polycarbolic acid or a copolymer polycarbolic acid (A), (ii) the polyester side chains comprises the components (B1) C | 2012-03-15 |
20120065120 | CLEANING AND CORROSION INHIBITION SYSTEM AND COMPOSITION FOR SURFACES OF ALUMINUM OR COLORED METALS AND ALLOYS THEREOF UNDER ALKALINE CONDITIONS - The present invention relates to corrosion inhibitor systems, in particular to cleaning and corrosion inhibiting compositions for surfaces of aluminum or colored metals and alloys thereof under alkaline conditions, especially in the food and pharmaceutical industries. The cleaning and corrosion inhibiting compositions comprise as a corrosion inhibitor at least one alkyleneoxy alkylphosphate di- or triester having the general formula | 2012-03-15 |
20120065121 | POST-CARBONATED CLEANING COMPOSITION AND METHOD OF USE - A post-carbonated cleaning solution which is prepared by first mixing at least one acid and two or more carbonate salts in an effective amount of water in such a manner that the carbon dioxide caused by the chemical reaction of the mixture is allowed to escape the solution. The resulting post-carbonated solution is a multiple surface cleaning composition that does not need to be maintained in a pressurized vessel and has a toxicity level of less than one. It uses none of the typical cleaning compounds to effect proper cleaning This post carbon dioxide aqueous solution can be concentrated to a point of near chemical saturation and the pH can be incrementally adjusted from about 3 to about 11. Citric acid is the preferred solid acid and sodium bicarbonate and sodium carbonate are the preferred carbonate salts. | 2012-03-15 |
20120065122 | Pharmaceutical Composition and Method for Modulating Slow Myosin - The present invention directed to a method for modulating the expression level of slow myosin comprising administering to a subject in need thereof a therapeutically effective amount of nuclear receptor interaction protein (NRIP) modulator and calmodulin, and a pharmaceutically acceptable carrier. | 2012-03-15 |
20120065123 | Synthetic Antibodies - Methods for synthetic antibodies, methods for making synthetic antibodies, methods for identifying ligands, and related methods and reagents. | 2012-03-15 |
20120065124 | CELL-PENETRATING PEPTIDES - A cell-penetrating peptide of (A) to (D) below gives cell membrane permeability and transmucosal absorbability to a physiologically active substance:
| 2012-03-15 |
20120065125 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES - The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function. | 2012-03-15 |
20120065126 | Pharmaceutical Compositions Containing Antifungal Peptides - The invention relates to a pharmaceutical composition containing, in a pharmaceutical carrier, a peptide comprising at least one sequence motif of the following general formula (I) Hel1-HB-Hel2. The invention also relates to the use and production of said pharmaceutical compositions. | 2012-03-15 |
20120065127 | Novel Bacillus thuringiensis Gene with Lepidopteran Activity - The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of | 2012-03-15 |
20120065128 | CRYSTALLINE FORMS OF THE DI-SODIUM SALT OF N-(5-CHLOROSALICYLOYL)-8-AMINOCAPRYLIC ACID - The present invention relates to crystalline polymorphic forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid, pharmaceutical compositions containing the same, methods of preparing the same, and methods for facilitating the delivery of active agents with the same. | 2012-03-15 |
20120065129 | METHOD OF MASS PRODUCING GROWTH FACTOR USING ADIPOSE DERIVED ADULT STEM CELLS - The present invention relates to a method for producing large amounts of human growth factors from human adipose-derived stem cells. More specifically, the invention provides a method capable of synthesizing human growth factors in significantly large amounts by culturing adipose-derived stem cells extracted from human adipose cells in suitable media and conditions. Also, stem cell culture media produced according to the method of the invention, and human growth factors isolated from the culture media, can be advantageously used as raw materials for drugs and cosmetics. | 2012-03-15 |
20120065130 | METHODS FOR TREATING CONGESTIVE HEART FAILURE - The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene. | 2012-03-15 |
20120065131 | COMPOSITIONS AND METHODS FOR TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF AN OLIGOPEPTIDE - The invention relates to the transdermal application of oligopeptides for reducing synaptic transmission in tissues of an animal. In one aspect, this invention relates to compositions comprising an oligopeptide and optionally a carrier comprising a positively charged “backbone” having positively charged branching or “efficiency” groups, as described herein. Most preferably the positively charged carrier is a long-chain positively charged polypeptide or a positively charged nonpeptidyl polymer, for example, a polyalkyleneimine. The invention further relates methods for producing a biologic effect of reducing synaptic transmission in a tissue by topically applying an effective amount of such a composition, preferably to the skin, of a subject or patient in need of such treatment. This invention also provides kits for preparing or formulating a composition that comprises the oligopeptide and optionally a carrier, as well as such additional items that are needed to produce a usable formulation, or a premix that may in turn be used to produce such a formulation. | 2012-03-15 |
20120065132 | METHOD OF TREATING OR PREVENTING TISSUE DETERIORATION, INJURY OR DAMAGE DUE TO CONGESTIVE HEART FAILURE - A method of treatment for treating, preventing, inhibiting or reducing tissue deterioration, injury or damage due to congestive heart failure disease, or for restoring tissue adversely affected by said disease, in a subject, includes administering to a subject an effective amount of a composition including a peptide agent including amino acid sequence LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2], a conservative variant thereof, or a peptide agent that stimulates production of an LKKTET [SEQ ID NO: 1] or LKKTNT [SEQ ID NO: 2] peptide, or a conservative variant thereof, in the tissue. | 2012-03-15 |
20120065133 | Artificial Oxygen Transport Protein - This invention provides heme-containing peptides capable of binding molecular oxygen at room temperature. These compounds may be useful in the absorption of molecular oxygen from molecular oxygen-containing atmospheres. Also included in the invention are methods for treating an oxygen transport deficiency in a mammal. | 2012-03-15 |
20120065134 | CD40-L INHIBITORY PHYLOMER PEPTIDES - The present invention provides compositions comprising peptidyl inhibitors of CD40L-dependent signalling that are not derived from a natural binding partner of CD40L such as CD40, or from a native CD40-CD40L interface. More particularly, the peptidyl inhibitors of the present invention are derived from natural sources that do not express CD40-CD40L costimulatory pathways. The invention also provides synthetic derivatives and analogs of the peptidyl inhibitors having enhanced binding affinity for CD40L or enhanced inhibitory activity relative to their parent molecules. | 2012-03-15 |
20120065135 | Genetically Modified TFPI And Method Of Making The Same - The present invention provides long half life genetically modified TFPI sequences (LTFPI) for anticoagulation. On the genetically modified TFPI sequence, the lysine at the carboxy-terminal sites 241, 254, 260 and 261 are replaced by alanin and the amino acid asparagine at glycosylation sites 117, 167, 228 and the amino acids serine and threonine at glycosylation sites 174 and 175 are substitutionally mutated. The present invention also provides methods of making the LTFPI through high efficient LTFPI expression from yeast production system. | 2012-03-15 |
20120065136 | RECOMBINANT FACTOR VIII HAVING ENHANCED STABILITY FOLLOWING MUTATION AT THE A1-C2 DOMAIN INTERFACE - The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed. | 2012-03-15 |
20120065137 | THERAPEUTICS FOR TRAUMA INDUCED FACTOR V CONSUMPTIVE COAGULOPATHY - A process of treating trauma induced factor V consumptive coagulopathy is presented whereby a subject is administered a preparation of isolated factor V or a variant thereof. Administration of factor V surprisingly improves clot times and reduces the severity and propensity of bleeding events. | 2012-03-15 |
20120065138 | LIPIDS, LIPID COMPLEXES AND USE THEREOF - The present invention is related to a compound according to formula (I), | 2012-03-15 |
20120065139 | GQ PROTEIN COMPETITIVE INHIBITORY POLYPEPTIDES, PREPARATION METHODS AND USES THEREOF - Provided are a series of Gq protein competitive inhibitory polypeptides (GCIPs), polynucleotides encoding them, and preparation methods thereof. Also provided are pharmaceutical compositions comprising GCIP polypeptides and their uses in the manufacture of drugs for treating myocardial hypertrophy. | 2012-03-15 |
20120065140 | Biomarkers for the Diagnosis of Autoimmune Disease - Compositions and methods are provided for diagnosis and treatment of rheumatoid arthritis. Defects in T cell receptor signaling lower the activation threshold of RA T cells, thus predisposing for a failure in maintenance of immune tolerance. Overexpression of B-Raf and/or K-Ras in CD4 T cells lowers the threshold to respond to TCR triggering in the absence of costimulation and increases responses to citrullinated peptides and other autoantigens. | 2012-03-15 |
20120065141 | STABILIZED BIODEGRADABLE NEUROTOXIN IMPLANTS - Biodegradable neurotoxin implants and methods of making and using such implants are provided. Biodegradable neurotoxin implants include a neurotoxin, a biodegradable polymer component, and an acidity regulating component. The biodegradable polymer component is effective in controlling the release of the neurotoxin from the implant when the implant is located in a patient's body. The acidity regulating component is effective in maintaining a pH of the implant in a desired range that may be effective in stabilizing the neurotoxin as the implant biodegrades when the implant is located in a patient's body. In one embodiment, an implant includes a | 2012-03-15 |
20120065142 | NOVEL SOLID MATERIALS OF AND METHODS FOR OBTAINING THEM - The instant invention relates to novel solid materials of {[(2S,5R,8S,11S)-5-Benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid}, methods for producing them, and the use of said solid materials in pharmaceuticals. | 2012-03-15 |
20120065143 | Dose and localization of botulinum toxins in skin and muscle - A novel dosing regimen for the administration of botulinum toxin based on the pattern, quantity, and location of neuromuscular junctions in the target tissue. Because the number of neuromuscular junctions in a target tissue remains generally stable throughout life and because the pharmacological effect of botulinum toxin is localized at the neuromuscular junction, dosing efficacy is unaffected by muscle mass, age of the patient, or body weight. | 2012-03-15 |
20120065144 | Peptide for the Prophylactic or Therapeutic Treatment of Skin Tumors in Initial Stages - It comprises an inhibitor peptide of TGF-β1 for use in preventive or therapeutic treatment of skin tumors at early stages, in which the peptide is disitertide or a derivate thereof, and a pharmaceutical composition that comprises a therapeutically effective amount of the peptide. | 2012-03-15 |
20120065145 | ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER - This application provides compositions and methods useful in the treatment of certain cancers. In part, this application is based on the recognition that certain molecules that target abasic lesions or AP sites in DNA improve, augment, or potentiate the chemotherapeutic efficacy of certain anticancer agents. | 2012-03-15 |
20120065146 | PEPTIDE MIMETIC LIGANDS OF POLO-LIKE KINASE 1 POLO BOX DOMAIN AND METHODS OF USE - Found in various eukaryotic organisms, polo-like kinases (collectively, Plks) are a conserved subfamily of Ser/Thr protein kinases that play critical roles in cell proliferation. Provided herein are compounds that specifically inhibit the activity of Plks, specifically Plk1. Further provided herein are methods for use of the compounds for the treatment of hyperproliferative disorders, particularly cancer. Also provided are uses of the compounds for the preparation of a medicament. | 2012-03-15 |
20120065147 | USE OF THE GTPASE RAB27B TO DIAGNOSE AND TREAT POOR PROGNOSIS ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER - The present invention relates to evaluating the prognosis of patients with estrogen receptor-positive breast cancer on the basis of Rab27B expression. The invention further relates to a kit comprising an assay for measuring Rab27B levels in said patients and to the usage of Rab27B as a target to screen for drugs capable of inhibiting or diminishing metastasis of said cancer. Furthermore, the invention discloses compounds which can be used to treat estrogen receptor-positive breast cancer. | 2012-03-15 |
20120065148 | PHOSPHODIESTERASE 4D7 AS PROSTATE CANCER MARKER - The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a corresponding method and immunoassay, a method for diagnosing, monitoring or prognosticating hormone-resistant prostate cancer vs. hormone-sensitive prostate cancer, a corresponding immunoassay, a method of data acquisition, an immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer disease, an immunoassay for stratifying an individual with prostate cancer, as well as a pharmaceutical composition comprising a compound directly stimulating or modulating the activity of PDE4D7, a compound indirectly stimulating or modulating the activity of PDE4D7, the PDE4D7 protein or a biologically active equivalent thereof, a nucleic acid encoding and expressing PDE4D7, a miRNA inhibitor specific for PDE4D7 miRNAs, a demethylation agent and/or a phosphodiesterase displacement factor. | 2012-03-15 |
20120065149 | Vitamin receptor binding drug delivery conjugates - The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described. | 2012-03-15 |
20120065150 | Neuroprotective effects of 2DG in Traumatic Brain Injury - This invention provides methods for reducing the extent and progression of traumatic brain injury and its deleterious sequellae specifically cognitive decline, post-traumatic epilepsy, post-traumatic stress disorder, and other adverse consequences depending on the progression of the initial injury, comprising administering to a TBI victim in need thereof a therapeutically-effective amount of an antiglycolytic compound, particularly 2-deoxyglucose (2-DG) or glycolysis-inhibiting analogs thereof. The invention also provides pharmaceutical compositions of 2-DG or glycolysis-inhibiting analogs thereof for use in the methods of the invention. | 2012-03-15 |
20120065151 | Substances Mixture, Use and Infusion Solution - The present disclosure relates to a substance mixture, wherein the substance mixture contains ribose, alanine, nicotinic acid and ascorbic acid. | 2012-03-15 |
20120065152 | PRODRUGS OF GUANFACINE - Prodrugs of guanfacine, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for improving the pharmacokinetics of guanfacine or minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration are provided herein. | 2012-03-15 |
20120065153 | AZASUGAR DERIVATIVES, HEPARANASE INHIBITORS, METHOD FOR PREPARING SAME, COMPOSITIONS CONTAINING SAME, USE THEREOF - The invention concerns heparanase inhibiting compounds of general formula (I) wherein R represents a hydrogen atom, an hydroxyl radical, a —OSO | 2012-03-15 |
20120065154 | Pyrazolo Pyrimidine Derivatives and Methods of Use Thereof - This invention generally relates to pyrazolo pyrimidine derivatives useful as, inter alia, inhibitors of short chain dehydrogenase/reductase (SDR) family of NAD(P)(H) dependent oxido-reductases. More specifically, the invention relates to pyrazolo pyrimidine derivatives, including derivatives and analogs of SDR inhibitors, pharmaceutical compositions containing derivatives and analogs of SDR inhibitors, methods of making derivatives and analogs of SDR inhibitors and methods of use thereof. | 2012-03-15 |
20120065155 | A3 ADENOSIDE RECEPTOR AGONISTS FOR THE REDUCTION OF INTRAOCULAR PRESSURE - The present disclosure provides the use of an A3R agonist, such as IB-MECA, for reducing in a subject, preferably, human subject, intra ocular pressure (IOP). Similarly, the invention provides a pharmaceutical composition and a method for reducing IOP in a subject making use of the A | 2012-03-15 |